Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2094258 Target Snapshot

Nuclear factor NF-kappa-B complex · PROTEIN COMPLEX GROUP · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,988Compounds
224Assays
4Approved Drugs
1,413.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Nuclear factor NF-kappa-B complex shows late clinical disease relevance led by Duchenne muscular dystrophy. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q00653. Start with Duchenne muscular dystrophy, then reuse UniProt Q00653 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Duchenne muscular dystrophy, then reuse UniProt Q00653 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Duchenne muscular dystrophy

Nuclear factor NF-kappa-B complex shows late clinical disease relevance led by Duchenne muscular dystrophy. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Duchenne muscular dystrophy because it currently carries late clinical support. Linked drugs include EDASALONEXENT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nuclear factor NF-kappa-B complex as ChEMBL target CHEMBL2094258, mapped to UniProt Q00653. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nuclear factor NF-kappa-B complex
PROTEIN COMPLEX GROUP · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2094258
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q00653
Nuclear factor NF-kappa-B p100 subunit
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Nuclear factor NF-kappa-B complex is the right protein anchor across sources, using UniProt Q00653 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Duchenne muscular dystrophy is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameNuclear factor NF-kappa-B complex
Target TypePROTEIN COMPLEX GROUP
OrganismHomo sapiens
UniProtQ00653
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNuclear factor NF-kappa-B p100 subunit
UniProt AccessionQ00653
Component TypeProtein
Sequence Length900 aa

Nuclear factor NF-kappa-B p100 subunit

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Nuclear factor NF-kappa-B complex, mapped to UniProt Q00653. ChEMBL maps the protein component as Nuclear factor NF-kappa-B p100 subunit. Sequence length is 900 aa.

Mapped IDQ00653
Review nameNuclear factor NF-kappa-B complex
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Nuclear factor NF-kappa-B complex shows late clinical disease relevance led by Duchenne muscular dystrophy. 1 more disease program remain visible in the same review block.

Late clinical Phase III
Duchenne muscular dystrophy
1 linked drug · 1 direct · 1 efficacy
Linked drugEDASALONEXENT
Clinical signal Phase I
type 2 diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugEDASALONEXENT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Duchenne muscular dystrophy because it currently carries late clinical support. Linked drugs include EDASALONEXENT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseDuchenne muscular dystrophy
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
7
Phase III
3
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50405.0
EC501,007.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5080827 10.6 IC50 0.025 Preclinical
CHEMBL329415 10.37 Kd 0.043 Preclinical
CHEMBL392438 10.22 IC50 0.06 Preclinical
CHEMBL384467 9.3 IC50 0.5 Approved
CHEMBL5532458 8.72 IC50 1.9 Preclinical
CHEMBL337665 8.52 IC50 3.0 Preclinical
CHEMBL2141296 8.21 IC50 6.2 Clinical
CHEMBL129857 8.1 IC50 8.0 Preclinical
CHEMBL5279887 8.05 EC50 9.0 Preclinical
CHEMBL3218834 8.05 IC50 9.0 Preclinical
Distribution

pChEMBL Value Distribution

308
5.0
370
5.5
174
6.0
61
6.5
40
7.0
13
7.5
9
8.0
2
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

VAMOROLONE
CHEMBL2348780
Approved 2023
Properties Compare Identifier
DEXAMETHASONE
CHEMBL384467
Approved 1958
Properties Compare Identifier
Assay Landscape

Assay Landscape

224
Total Assays
1,061
Tested Compounds
2
Assay Types
Binding — 220 assays, 254 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 191 239 5.9
protein complex format 14 10 6.5
tissue-based format 6 4 5.7
subcellular format 5 1 8.7
assay format 4 0 —
Functional — 4 assays, 1,061 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 1,016 5.5
cell-based format 2 45 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine